US › Healthcare

Biofrontera Inc (BFRI)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$1.24+2.48%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$12.0M

Revenue YoY

+32.9%

Net profit

$-604,000

EPS

$-0.05

EPS estimate

$-0.17

Net margin

-5.0%

EPS came in at -0.05 against a street estimate of -0.17 — a beat of 70.6%.

Key statistics

Market cap

$23.0M

Forward P/E

13.0

P/B

3.85

Book value

$0.42

EPS (TTM)

$-0.43

52-week high

$1.66

52-week low

$0.55

50-day MA

$1.29

200-day MA

$1.00

Beta

0.84

Analyst view

Analysts rate Biofrontera Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $6.00.

Shareholding

Insiders

11.99%

Institutions

20.72%

Largest institutional holders

Fund	Stake
Rosalind Advisors, Inc.	7.84%
AIGH Capital Management, LLC	4.98%
Geode Capital Management, LLC	0.74%
Citadel Advisors Llc	0.71%
Vanguard Fiduciary Trust Co	0.42%
Vanguard Capital Management, LLC	0.35%
Susquehanna International Group, LLP	0.26%
XTX Topco Ltd	0.15%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Biofrontera Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.